Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 11, 2004. The report discloses a share buyback executed under shareholder authority granted at the Annual General Meeting on May 19, 2003, and updates regarding director share interests.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. Specific transaction values disclosed include:
- Share Repurchase: 3,150,000 Ordinary 25 pence shares purchased for cancellation on March 9, 2004.
- Repurchase Price: 1,103.86 pence per share.
- Director Transaction: Director J.D. Coombe acquired 22 Ordinary Shares (11 personal, 11 company match) at a price of £11.08 per share on March 9, 2004.
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 3,150,000 shares. Additionally, there was a minor change in the shareholding interest of Director J.D. Coombe resulting from the ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items beyond the specific transactions noted above.
Investor Verification Points
- Verify the total cost of the 3,150,000 share repurchase against the stated price of 1,103.86 pence per share.
- Confirm the impact of the share cancellation on the total number of outstanding shares and earnings per share.
- Review the full terms of the ShareReward Plan to understand the mechanics of the director's share acquisition.